<DOC>
	<DOCNO>NCT01270191</DOCNO>
	<brief_summary>Whether GLP-1 GLP-1 receptor agonist produce sustained improvement beta-cell function follow short-term therapy currently know . This randomize , control trial carry assess efficacy short-term insulin therapy ( NPH injection twice daily ) compare GLP-1 analogue ( Exenatide injection twice daily ) glycemic control , remission rate , ß-cell function , long-term glycemic control newly diagnose type 2 diabetic patient moderate hyperglycemia .</brief_summary>
	<brief_title>The Effects Short-Term Exenatide Therapy Newly Diagnosed Type 2 Diabetic Patients</brief_title>
	<detailed_description>Background : There progressive deterioration beta-cell function type 2 diabetic , estimate islet function 50 % normal time diagnosis . The progressive nature type 2 diabetes one major challenge treatment affect patient , agent could alter natural history condition would add greatly current treatment approach . Short-term intensive insulin therapy newly diagnose type 2 diabetes improve beta-cell function usually lead temporary remission time . The acute effect GLP-1 GLP-1 receptor agonists beta-cells stimulation glucose-dependent insulin release , follow enhancement insulin biosynthesis stimulation insulin gene transcription . The chronic action stimulate beta-cell proliferation , induction islet neogenesis , inhibition ß-cell apoptosis , thus promote expansion beta-cell mass , observed rodent diabetes culture beta-cells . Objectives : Whether GLP-1 GLP-1 receptor agonist produce sustained improvement beta-cell function follow short-term therapy currently know . This randomize , control trial carry assess efficacy short-term insulin therapy ( NPH injection twice daily ) compare GLP-1 analogue ( Exenatide injection twice daily ) glycemic control , remission rate , beta-cell function , long-term glycemic control newly diagnose type 2 diabetic patient moderate hyperglycemia . Study Designs Methods : We recruit 80 newly diagnose type 2 diabetic patient moderate hyperglycemia , another 80 newly diagnose type 2 diabetic patient severe hyperglycemia receive intensive insulin therapy 10-14 day , randomize treat exenatide insulin injection . They visit clinic every 2 week first 2 visit every 4 week 20 week . After 24 week intervention , patient treat life style modification follow fast plasma glucose every month . Hyperglycemia relapse define fast plasma glucose 126 mg/dL confirm two week later . Patients hyperglycemia relapse treat metformin ( 500 mg per day 1500 mg per day ) gliclazide-MR added second step remain study period . A1C measurement perform baseline , 3 , 6 , 12 18 month , OGTT perform screen 6 month randomization . All subject continually followed-up clinic 5 year evaluate long-term glycemic control . The monotherapy failure define A1C &gt; 7.0 % metformin 1500 mg/day . The primary outcome one year time glycemic remission remission rate one year short-term therapy . The primary outcome 5 year monotherapy failure time monotherapy failure rate 5 year short-term therapy . The secondary outcome beta-cell function insulin sensitivity calculate OGTT , comparison A1C change , proportion subject reach treatment target ( A1C &lt; 7.0 % &lt; 6.5 % 1 5 year ) . These subject follow 5 year evaluate long-term glycemic control . Expected Results : We expect screen 100 patient , randomize 80 patient least 30 patient group complete one year follow-up . We expect short-term intensive treat insulin exenatide get good glycemic control accompany improve beta-cell function newly diagnose type 2 diabetes . We compare remission rate one year different short-term therapy . We evaluate effect beta-cell function long-term glycemic control . This study also assess readily available parameter would predict patient achieve long-term successful glycemic control correction glucose toxicity .</detailed_description>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>1 . Newly diagnose type 2 diabetic patient . 2 . Age 30 70 year old . 3 . HbA1C 7 9 % OPD patient 4 . If HbA1c &gt; 9.0 % blood glucose &gt; 300 mg/dL , intensive insulin therapy 1014 day 1 . Previous treat antidiabetic medication 2 . Pregnant lactation woman . 3 . Impaired liver function ( ALT &gt; 100 U/L ) 4 . Impaired renal function ( Serum creatinine &gt; 2.0 mg/dL ) 5 . Recently suffer MI CVA . 6 . Patients acute intercurrent illness . 7 . 2hour Cpeptide level &lt; 2.0 ng/mL . 8 . History severe hypersensitivity product component . 9 . History high risk acute pancreatitis . 10 . Now use warfarin .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Exenatide , Beta-Cell Function , Glycemic Control</keyword>
	<keyword>Newly Diagnosed Type 2 Diabetic Patients</keyword>
</DOC>